dmt imperial ms day 26 sept 2014 giovannoni gg1
DESCRIPTION
Presentation from MS Day at Twickenham hosted by Imperial.TRANSCRIPT
![Page 1: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/1.jpg)
Treating MS in 2014
Professor Gavin Giovannoni
Blizard Institute, Barts and The London School of Medicine and Dentistry
![Page 2: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/2.jpg)
Disclosures Professor Giovannoni has received personal compensation for participating on Advisory Boards in relation to clinical trial design, trial steering committees and data and safety monitoring committees from: Abbvie, Bayer-Schering Healthcare, Biogen-Idec, Canbex, Eisai, Elan, Fiveprime, Genzyme, Genentech, GSK, GW Pharma, Ironwood, Merck-Serono, Novartis, Pfizer, Roche, Sanofi-Aventis, Synthon BV, Teva, UCB Pharma and Vertex Pharmaceuticals.
Regarding www.ms-res.org survey results in this presentation: please note that no personal identifiers were collected as part of these surveys and that by completing the surveys participants consented for their anonymous data to be analysed and presented by Professor Giovannoni.
Professor Giovannoni would like to acknowledge and thank Biogen-Idec, Genzyme and Novartis for making available data slides on natalizumab, alemtuzumab and fingolimod for this presentation.
![Page 3: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/3.jpg)
www.ms-res.org
![Page 4: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/4.jpg)
Questions: the MSers perspective
To make an informed decision you need to ask and understand the following questions:
1. Are you sure that you have MS?
2. What types of MS do you have?
3. What prognostic group do you fall into?
4. What is the risk of not having any treatment?
5. Do you have active MS?
6. Am I eligible for treatment with a DMT?
7. Do you understand the difference between the treatment strategies of maintenance and escalation and induction therapy?
8. What is the therapeutic target?
9. Can we cure MS?
![Page 5: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/5.jpg)
Question: Are you sure that you have MS?
MS misdiagnosis rate of ~5%
Engell T. A clinico-pathoanatomical study of multiple sclerosis diagnosis. Acta Neurol Scand. 1988 Jul;78(1):39-44.
CDMS 485/518 (94%) - SENSITIVITY = True+ve /(True+ve + False-ve)
MS mimics
NMO
Shimizu et al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology. 2010 Oct 19;75(16):1423-7.
Migraine
Kleinschmidt-DeMasters et al. PML complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005 Jul 28;353(4):369-74
![Page 6: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/6.jpg)
Module Identifier
Question: What types of MS do you have?
Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996 Apr;46(4):907-11.
RRMS R-SPMS/NR-SPMS PPMS RPMS
relapsing forms of MS vs. non-relapsing MS
![Page 7: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/7.jpg)
Question: What prognostic group do you fall into?
Good prognosis Poor prognosis
Young
Female sex
Optic neuritis
Isolated sensory symptom
Full recovery from attack
Long interval to second
relapse
No disability after 5 years
Normal MRI / low lesion load
CSF negative for OCBs
Older age of onset
Male sex
“Multifocal“ onset
Efferent system affected (motor,
cerebellar, bladder)
High relapse rate in the first 2-5 years
Substantial disability after 5 years
Abnormal MRI with large lesion load
Genomic factors (e.g. ApoE4, KIF1B)
CSF positive for OCBs
Adapted from Miller et al., Lancet Neurology 2005: 4; 281-288
![Page 8: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/8.jpg)
Question: What prognostic group do you fall into?
Favourable
Indeterminate
Poor
time Aim of
treatment
![Page 9: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/9.jpg)
Relapsing-MS
Active Inactive Highly-active Rapidly-evolving severe
![Page 10: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/10.jpg)
Active Inactive HA RES
![Page 11: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/11.jpg)
A population of newly diagnosed CISers/MSers
![Page 12: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/12.jpg)
Long-term outcomes under the current Rx paradigm
![Page 13: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/13.jpg)
Long-term outcomes under the T2T-NEDA paradigm
![Page 14: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/14.jpg)
Question: What is the risk of not having any treatment?
MS is one of the most common causes of neurological disability in young adults2
Natural history studies indicate that it takes a median time of 8, 20 and 30 years to reach the irreversible disability
levels of EDSS 4, 6 and 7, respectively3
Up to 75% increased annualized divorce rate4
Life expectancy is reduced by 5-10 years5
7.5x greater than suicide rate than the general population6
2 out of 3 patients with RRMS were unemployed due to the disease7
Utilit
y
EDSS Status
EDSS and utilitya show a significant inverse relationship1,b
aUtility measures are derived from EQ-5D using the EuroQoL instrument. bAdapted from Orme et al 2007. Error bars depict 95% confidence intervals. Half points on EDSS are not shown on graph axis, except at EDSS 6.5.
1.Orme M et al. Value In Health. 2007;10:54-60. 2.WHO. 2008.[TK] 3. Confavreaux, Compston. 2005.[TK] 4. Coles et al. 2001.[TK] 5. Confavreaux, Vukusic. 2006.[TK] 6. Sadovnick et al. Neurology 1991;41:1193-6.
7. Morales-Gonzales. Mult Scler. 2004;10:47-54.
![Page 15: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/15.jpg)
Consequences of increasing EDSS scores: loss of employment1
0
10
20
30
40
50
60
70
80
90
Work Capacity by Disability Level
0.0/1.0 2.0 3.0 4.0 5.0 6.0 6.5 7.0 8.0/9.0
EDSS Score
Pro
po
rtio
n o
f P
ati
en
ts ≤
65
Ye
ars
Old
Wo
rkin
g (
%)
The proportion of patients employed or on long-term sick leave is calculated as a percentage of patients aged 65 or younger.
1. Kobelt G et al. J Neurol Neurosurg Psychiatry. 2006;77:918-926;
2. Pfleger CC et al. Mult Scler. 2010;16:121-126.
Spain
Sweden
Switzerland
United Kingdom
Netherlands
Italy
Germany
Belgium
Austria
~10 yrs2
![Page 16: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/16.jpg)
www.ms-res.org
![Page 17: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/17.jpg)
www.ms-res.org
![Page 18: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/18.jpg)
Question: Do you have active MS?
vs.
1
2
3
Clinical
MRI
Biomarkers
![Page 19: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/19.jpg)
Question: Am I eligible for treatment with a DMT?
MSer
Neurologist
Payers
Regulator
![Page 20: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/20.jpg)
Question: Am I eligible for treatment with a DMT?
![Page 21: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/21.jpg)
MS is an autoimmune disease hypothesis
15-20 year experiment
“hit hard and early ”
Question: Do you understand the difference between the treatment strategies of maintenance and escalation and induction therapy?
What is your treatment philosophy? maintenance-escalation vs. induction
survival analysis
![Page 22: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/22.jpg)
Treatment Selection & treating-2-target
Choosing therapy
X Y Z
Define the Individual’s MS
No
Treatment failure? Yes
• Patient’s preferences?
• Your choice?
Individual measures:
• Evidence of disease activity?
• Tolerability/safety?
• Adherence?
• Drug or inhibitory markers?
Monitoring
• MS prognosis
• Life style and goals
• Shared goals for therapy
Rebaseline
Rebaseline:
• IFNβ, natalizumab, fingolimod,
teriflunomide, DMF=3-6 months
• Glatiramer acetate=9 months
• Alemtuzumab=24 months
DMF=dimethyl fumarate.
![Page 23: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/23.jpg)
Treatment Ladder
1st-line A
1st-line B
1st-line C
1st-line D
1st-line E
2nd-line N
2nd-line M
3rd-line y
3rd-line X
![Page 24: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/24.jpg)
Case studies
![Page 25: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/25.jpg)
38-year-old teacher with relapsing–remitting MS under the care of a hospital in central London Glatiramer acetate treatment for 3 years (good adherence and tolerance) Relapse with a mild left sensory loss Referred to me for a second opinion Switched to interferon β (intramuscular interferon β-1a; www.msdecisions.org.uk) Mild persistent flu-like side effects and lymphopenia 12/12’s neutralizing antibodies screen negative Volunteers for new research programme, which included a gadolinium-enhanced MRI protocol
Teacher
![Page 26: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/26.jpg)
38-year-old teacher with relapsing–remitting MS As a result of fatigue and cognitive problems she is forced to take
early retirement Although fully functional she develops depression and anxiety In her spare time she spends a lot of time on the web and becomes
an expert patient Widely read
Net savvy; regular follower of www.ms-res.org
Teacher X
![Page 27: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/27.jpg)
![Page 28: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/28.jpg)
The relapsing MS DMT doughnut
CIS, clinically isolated syndrome; DMT, disease-modifying therapy; GA, glatiramer acetate; IFN, interferon; RIS, radiologically isolated syndrome; RRMS, relapsing–remitting MS.
Inactive RRMS
CIS
RIS or asymptomatic MS
Suboptimal responders?
Active
RRMS IFN β
or
GA
IFN β
Highly active RRMS Fingolimod Natalizumab
![Page 29: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/29.jpg)
Teacher X
![Page 30: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/30.jpg)
Teacher X
![Page 31: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/31.jpg)
Ian Rogers. ACNR 2007: 7(3);14.
Case 2
![Page 32: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/32.jpg)
Case 3
![Page 33: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/33.jpg)
What is the therapeutic target?
![Page 34: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/34.jpg)
No evident disease activity: NEDA
Gd, gadolinium. 1. Havrdova E, et al. Lancet Neurol 2009; 8:254–260; 2. Giovannoni G, et al. Lancet Neurol 2011; 10:329–337.
Treat-2-target
No evidence of disease activity defined as:1,2
× No relapses
× No sustained disability progression
× No MRI activity
× No new or enlarging T2 lesions
× No Gd-enhancing lesions
![Page 35: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/35.jpg)
Relapses
Unreported relapses
Clinical disease progression
Subclinical relapses: focal MRI activity
Focal gray and white matter lesions not detected by MRI
Brain atrophy
Spinal fluid neurofilament levels
MS Iceberg
Clinical activity
Focal MRI activity
Hidden focal and diffuse MRI activity
Microscopic or biochemical pathology
Biomarkers
![Page 36: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/36.jpg)
Control Multiple sclerosis
![Page 37: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/37.jpg)
Brain atrophy occurs across all stages of the disease
De Stefano, et al. Neurology 2010
n= 963 MSers
![Page 38: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/38.jpg)
Treatment effect on disability predicted by effect on T2-lesion load and brain atrophy
Meta-analysis of treatment effect on EDSS worsening (y) vs effects on MRI lesions
and brain atrophy, individually or combined, in 13 placebo-controlled RRMS trials
(13,500 patients)
Sormani MP et al. Ann Neurol. 2014;75:43-49.
![Page 39: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/39.jpg)
Which drugs slow the rate of brain atrophy in MSers?
1. Interferon beta a. Betaferon x b. Avonex ? c. Rebif x
2. Glatiramer acetate (Copaxone) x 3. Mitoxantrone (Novantrone) x 4. Natalizumab (Tysabri) 5. Fingolimod (Gilenya) 6. Teriflunomide (Aubagio) x 7. Alemtuzumab (Lemtrada) 8. Dimethyl-fumarate (Tecfidera) ?
![Page 40: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/40.jpg)
Rheumatoid arthritis End-stage joint disease
![Page 41: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/41.jpg)
Can you cure MS?
![Page 42: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/42.jpg)
To cure MS do we need to know the cause?
EBV Vitamin D
Smoking Genes
![Page 43: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/43.jpg)
We work on the hypothesis that MS is an autoimmune disease.
Multiple
Sclerosis
Environ-ment
Genes
![Page 44: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/44.jpg)
The autoimmune hypothesis
Multiple
Sclerosis
Environ-ment
Genes
![Page 45: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/45.jpg)
Survival Curves
85%
50%
30%
0%
15yrs 25yrs 40yrs 50yrs
100% Benign MS
Proportioned of treated MSers are cured
Natural history
Unrealistic expectation
Delayed onset of SPMS
![Page 46: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/46.jpg)
Defining a cure: a working definition
85%
50%
30%
0%
15yrs 25yrs 40yrs 50yrs
100%
Proportioned of treated MSers are cured
Natural history
NEDA = no evident disease activity
![Page 47: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/47.jpg)
survival analysis
“highly effective treatments”
MS is an autoimmune disease hypothesis
15-20 year experiment
Can we repeat the animal experiment in MS?
Multiple
Sclerosis
Environ-ment
Genes
![Page 48: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/48.jpg)
Neuro-restoration
Remyelination
Neuroprotection
Anti-inflammatory
Therapeutic pyramid
Anti-ageing
Brain
Health
Initiative
![Page 49: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/49.jpg)
MRI Events
1st clinical attack
Time (Years)
Subclinical disease
Inflammation
Brain volume loss
Neuroaxonal loss
Dis
eas
e S
eve
rity
SPMS RRMS
1st MRI lesion
Relapses
CIS RIS R-SPMS
RIS = radiologically isolated syndrome; CIS = clinically isolated syndrome, RRMS = relapsing-remitting MS; R-SPMS = relapsing secondary progressive MS; SPMS = secondary progressive MS; PPMS = primary progressive MS
SPMS: Natalizumab, Siponimod, DMF
Late SPMS: SMART STUDY fluoxetine, amiloride, riluzole
Early SPMS: PROXIMUS oxcarbazepine
CIS: PHENYTOIN RRMS: ? DE-FLAMES STUDY
PPMS
PPMS: Fingolimod, Ocrelizumab, Laquinimod
SP&PPMS: Ibudilast
![Page 50: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/50.jpg)
Giovannoni & Cutter; Lancet Neurol 2006; 5: 887–94.
T2T-NEDA diffusion curve
• MSer
• Neurologist
• Payers
• Regulator
![Page 51: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/51.jpg)
![Page 52: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/52.jpg)
Have we got it wrong?
EBV Vitamin D
Smoking Genes
Multiple
Sclerosis
Environ-ment
Genes
Is MS due to a virus?
Charcot Project
INSPIRE Trial (Raltegravir)
Etc. etc. etc.
![Page 53: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/53.jpg)
Nogo, MAG, OMgP
Lingo-1-NgR-p75NTR
GAP-43
NCAM
Neuregulin
Agents in trial: • Benztropine: anticholinergic
• BIIB033: anti-LINGO-1
• Clemastine: anti-histamine
• GSK239512: histamine H(3)
receptor antagonist
• IRX4204 & Bexarotene:
RXR-agonist
• rHIgM22: oligodendrocyte
target
• VX15: anti-SEMA4D Courtesy of Sharmilee Gnanapavan, MBBS, BmedSci, PhD.
Remyelination
![Page 54: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/54.jpg)
Markers of Remyelination
Image courtesy of Klaus Schmierer.
3 6 9 12 24
EDSS
0
TIME
Active (confirmed improvement)
Placebo (confirmed progression)
Exit EDSS showing improved function
Shadow plaque MRI - MTR
Schmierer et al. Ann Neurol 2004;56:407–415.
![Page 55: Dmt imperial ms day 26 sept 2014 giovannoni gg1](https://reader033.vdocuments.us/reader033/viewer/2022061202/547cb61fb4af9fa5158b512d/html5/thumbnails/55.jpg)
Conclusions
MS is a bad disease – Mortality, disability, unemployment, divorce, suicide cognitive impairment,
etc.
Era of individualised profiling – Prognosis, risk, treatment and monitoring
New treatment paradigm – Maintenance vs. induction therapy
– Therapeutic ladder vs. early highly-effective treatments as a 1st-line option
– Improved risk mitigation tools
– New treatment paradigm of treat-2-target of NEDA or no evidence of disease activity
– Future target to prevent organ damage
Is it fair to make MSers wait 20 years for the outcome of an ongoing experiment?
Watch out for a black swan?